Brain Targeting Through Intranasal Route: An Overview

Sorakayala Venkata Anusha¹, Jonnala Ratna¹, Srirama Swarnalatha¹ and Maruvajala Vidyavathi¹

¹Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam, Tirupati, India.

Authors’ contributions

This work was carried out in collaboration among all authors. Authors SVA and MV designed the study, performed the statistical analysis, wrote the protocol, author JR wrote the first draft of the manuscript. Author SS managed the Collection of data. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i34B31853

Received 20 April 2021
Accepted 25 June 2021
Published 02 July 2021

ABSTRACT

Brain targeting has always been challenging due to the presence of physiological barriers by changing the integrity of these barriers, so as to allow the toxic substances, bacteria and viruses into the brain, which may severely damage the central nervous system. This problem can be reduced by delivering drugs through the intra nasal route, which by passes the blood brain barrier and reaches into the brain. Nasal route is a non-invasive type, widely used for the local treatment as well as used for systemic therapy as drug delivery directly goes in to systemic circulation. Nasal route provides good absorption of small molecules compared to that of large molecules, absorption of small molecules and large molecules can be increased by absorption promoters. Different drug delivery devices are developed for nasal administration like liquids, semi-solid and solid formulation are consider to deliver the drugs to treat most of the CNS diseases (i.e. Parkinson’s, Alzheimer’s disease) because it requires specific targeting of drugs to the brain. This review highlighted the challenges, approaches for brain targeting and various drug delivery systems developed with different drugs targeting to brain through nasal administration.

Keywords: Brain targeting; CNS diseases; blood brain barrier; drug delivery devices; nasal route.

*Corresponding author: E-mail: vidyasur@rediffmail.com;
1. INTRODUCTION

In Targeted drug delivery system the medicament is selectively delivered to the particular site of action without reaching to the non target organs. It is a method of delivering medication to a patient that increases the concentration of drug in body parts and to reduce the side effects [1]. Targeting to brain is a major challenge because it is separated from the circulating blood by a unique membranous barrier called as blood brain barrier. which is a highly semi permeable membrane [2]. Any disorder (or) diseases related to brain are difficult to control because it is covered by the blood brain barrier. Which doesn’t allow the 100% of large molecules and 98% of small molecules [3]. The blood brain barrier consists of tight junctions around the capillaries and actively transport the metabolic products such as glucose crosses the barrier with specific proteins [4]. There are different factors responsible for crossing the blood brain barrier like binding of the drug to a transporter, opening and closing of ion channels, lipophilicity, enzymatic degradation of drugs, higher molecular weight of drugs and the presence of functional groups. These are the factors which determine the blood brain barrier permeability of any drugs [5].

1.1 Objectives of Brain Targeting

Central nervous system disorders are one of the leading cause of illness requiring more extended care and hospitalization. It has been estimated that around 10 million people in the world are living with Parkinson’s disease and the number of central nervous system related disorders are rising day by day [6]. Treating central nervous system diseases such as Parkinson’s disease, Alzheimer’s disease, Schizophrenia, Stroke, Epilepsy, Brain tumours is extremely difficult due to the presence of various barriers mainly the blood brain barrier which restricts the passage of drug into the brain. Investigating a suitable drug delivery system which could allow the drug to bypass the barriers and enter the drug into brain for the management of brain diseases is a big challenge [7].

2. METHODOLOGY

2.1 Approaches for Brain Targeting

Actual treatment of CNS disorders, such as brain tumours, psychological disorders and neuro degenerative disorders depends on successful delivery of drug to the brain. Lipid soluble molecules with a molecular mass under 400-600 Da can easily enter through the tight junction of the blood brain barrier [8]. However, water soluble molecules with a mass of less than 600 Da may enter into the brain through carrier mediated transport, receptor mediated transport (or) absorptive mediated transport. The three different approaches currently used to deliver the drug into brain without systemic toxicity are Invasive Approach, Pharmacological Approach and Biological (or) physiological approach [9].

2.2 Invasive Approach

The invasive approach is a physical approach in which peptides and nutrients having poor bioavailability in the brain after intravenous (or) oral administration are made bioavailable by using different techniques like intra cerebro ventricular infusion (drug is directly injected into the cerebral lateral ventricles resulting in diffusion of drugs into the brain through the cerebrospinal fluid) [10]. Convection enhanced delivery (In which the drug is delivered directly into brain parenchymal cells, with the help of stereotactic apparatus) [11]. Intra cerebral injection (or) brain implants (It is a direct method to deliver drug into target site of brain) The drugs such asNitrosourea, Methotrexate, Mitoxantrone, Carmustine were used for brain targeting by using invasive approach [12,13].

In certain cases the blood brain barrier is mechanically reached by applying osmotic shock, MRI guided focused ultrasound blood brain barrier disruption [14].

2.3 Pharmacological Approach

The pharmacological approach is used for lipid insoluble, high molecular weight drug molecules by chemical techniques with the modification of the chemical structure of the drug to improve lipophilicity, (or) by converting into prodrug form to reach the active site in the brain. The other pharmacological approach is development of colloidal drug carriers such as nanoparticles, micelles, liposomes, emulsions and dendrimers to effectively transport the drugs across the blood brain barrier by various trans cellular mechanisms. Paclitaxel loaded micelles, Doxorubicin loaded liposomes, Quercetin loaded solid lipid nanoparticles, Lamuvidine loaded dendrimers were developed for brain targeting by using pharmacological approaches [15].
2.4 Biological (or) Physiological Approach

Biological (or) physiological approaches are based on the transport of different molecules by specific transporters such as insulin receptors, transferrin receptors etc. These physiological approaches are a) Cell penetrating peptide mediated drug delivery (amino acids with a positive charge are used to transport the drug molecules into the cytoplasm by different mechanisms). Methotrexate was used for brain targeting through cell penetrating peptide delivery. b) Receptor mediated drug delivery (Receptors such as transferrin receptor and insulin receptor are targeted by specific ligands and antibodies which will transfer the drugs into the brain). Loperamide was used for brain targeting through receptor mediated delivery [16]. c) Adsorptive mediated drug delivery (Various peptide vectors are developed for adsorption endocytosis to deliver peptides and proteins for treating brain tumours). Cisplatin was used for brain targeting through adsorptive mediated drug delivery [17].

2.5 Intra Nasal Route

Drugs and its delivery systems are administered through different routes based on different approaches like oral, injections and nasal route etc. Intra nasal route has been considered as a important route to achieve faster drug absorption because nasal mucosa is permeable to different compounds than the gastro intestinal tract due to lack of pancreatic and gastric enzymatic activity, neutral pH of the nasal mucosa and less dilution unlike by gastro intestinal contents. Many drugs have been shown to achieve better systemic bioavailability through nasal route than by oral administration. The nasal route avoids hepatic first pass elimination and is easily available with self-medication. Rapid drug absorption and quick onset of action are achieved with the nasal route. The bioavailability of larger drug molecules can be improved by using absorption enhancers [18]. Drugs having more than 300 Daltons molecular weight are suitable for nasal administration and better nasal permeability. PH of the nasal formulation should be adjusted to 4.5-6.5 to avoiding nasal irritation.

2.5.1 Brain targeting by intra nasal route

The movement of molecules from the nasal cavity to the brain parenchyma occurs along with the olfactory nerves. Once the molecules are delivered to the origin of the nerves in the cerebrum and they are able to distribute through the brain. This process occurs via two pathways intracellular and extra cellular mechanisms. Intra cellular mechanism involves internalization of the molecule by an olfactory neuron, movement of the endocytic vesicle with in the cell to the neuron projection site and finally release via exocytosis. Where as extra cellular pathway involves crossing of drug through the nasal epithelium to the lamina propria by bulk flow process. The axon leads into the central nervous system, where the drug is distributed further via fluid movement [19].

2.6 Pharmaceutical Approach

For intra nasal administration of drugs, four basic formulations are considered i.e. solution, suspension, emulsion, gels and dry powders [20]. These are administered through nose using different devices like catheters, nebulizers, squeezed bottles, insufflators, dry powder inhalers and metered dose inhalers. There are different particulate (nano, micro) novel drug delivery systems are being developed for targeting to brain through nasal route to improve bioavailability with fast action. These include nanoparticles, nano emulsions, solid lipid nanoparticles, liposomes etc [21].

3. DISCUSSION

The present review is focusing on different novel (nano and micro particulate) drug delivery systems developed with various drugs for brain targeting by intra nasal administration to treat CNS disorders as given in Table 1. Based on the Table 1, it was found that, 50% of developed delivery systems belong to nano drug delivery systems, 20% micro particulate systems and remaining include gels, micelles etc. Among nano drug delivery systems, 27% of Solid lipid nanoparticles (SLNs), 18% of Nanoparticles, 9% of Nanoemulsion and 2% of Nano liposomes were developed for intra nasal administration as shown in Fig. 1. Based on the table, it was demonstrated that 20.31% drugs (Astataxanthin, Galanatamine hydrochloride, Donepezil, Venlafaxine, Valproicacid, Thymoquinone, Hyaluronic acid, Rivastigmine) were selected for the treatment of Alzheimer's disease, 18.75% for the treatment of Epilepsy and status epilepticus, 12.5% for the treatment of Schizophrenia and 9.4% for the treatment of Depression by intranasal administration. Most of the reports identified that higher concentration of drug in
### Table 1. List of drugs developed into nasal drug delivery systems for brain targeting

| S. No | Drug name         | Drug delivery system         | Name of the disease        | Result                                                                 | Reference |
|-------|-------------------|------------------------------|---------------------------|----------------------------------------------------------------------|-----------|
| 1.    | Arthemether       | Nanoparticles                | Cerebral malaria          | Exhibit sustained release and higher concentration of drug in brain upon intra nasal administration was observed. | [22]      |
| 2.    | Astaxanthin       | SLNs                         | Alzheimer’s & Parkinson’s Disease | Improved brain targeting efficiency of drug was observed.              | [23]      |
| 3.    | Agomelatine       | SLNs                         | Depression                | Enhanced absolute bioavailability and successful brain targeting by the intra nasal route was estimated. | [24]      |
| 4.    | Almotriptan malate| SLNs                         | Migraine                  | Enhanced the nasal residence time and formulation was safe for nasal administration. | [25]      |
| 5.    | Bromocriptine     | Nano particulate formulation | Parkinson’s disease       | Enhanced drug bioavailability and direct targeting to the brain was observed. | [26]      |
| 6.    | Carbamazepine     | Polymeric hybrid Nanoparticles | Epileptic seizures        | Good targeting efficiency and improved bioavailability was observed.              | [27]      |
| 7.    | Diazepam          | Nanoparticles                | Status epileptics         | Significantly higher brain uptake of drug was observed.                | [28]      |
| 8.    | Duloxetine        | Nano structured lipid carriers | Depression                | Increased nasal residence time and higher amount of drug in brain were found. | [29]      |
| 9.    | Donepezil         | SLNs                         | Dementia                  | Achieved sustained release and increased brain targeting potential was observed. | [30]      |
| 10.   | Donepezil         | Nano emulsion                | Alzheimer’s Disease       | Increased penetration of drug through nasal mucosa and improved brain delivery was observed. | [31]      |
| 11.   | Donepezil         | SLNs                         | Alzheimer’s disease       | Drug delivery system with sustained release and localization of drug in brain was observed. | [32]      |
| 12.   | Doxorubicin       | Lipid nano carriers          | Glioblastoma              | High quality, safety and efficacy of the developed delivery system was observed. | [33]      |
| 13.   | Efavirenz         | SLNs                         | HIV/AIDS                  | Increased concentration of drug in brain was observed.                | [34]      |
| S. No | Drug name              | Drug delivery system | Name of the disease | Result                                                                 | Reference |
|-------|------------------------|----------------------|---------------------|----------------------------------------------------------------------|-----------|
| 14    | Embelin                | Nano structured lipid carriers | Epilepsy            | Achieved sustained release and higher concentration of drug into brain was found. | [35]      |
| 15    | Galantamine hydrochloride | SLNs                | Alzheimer’s disease | 2 fold improvement in the bioavailability of the drug was observed. | [36]      |
| 16    | Haloperidol            | SLNs                | Schizophrenia       | Controlled and sustained release with better brain targeting efficiency was estimated. | [37]      |
| 17    | Hyaluronic acid        | Nano emulsion       | Alzheimer’s Disease | Nano emulsion was safe on intra nasal administration and increased amount of drug in the brain was observed. | [38]      |
| 18    | Lorazepam              | Polymer nanoparticles | Epilepsy            | Gamma scintigraphy studies showed that high uptake of nanoparticles in to brain. | [39]      |
| 19    | Lorazepam              | Nanoparticles       | Epilepsy            | Increased patient compliance for the easy and non-invasive route of administration was observed. | [40]      |
| 20    | Olanzapine             | Nanoparticles       | Schizophrenia       | The results proved that the drug concentration increased in brain was observed. | [41]      |
| 21    | Pramipexole dihydrochloride | Nanoparticles   | Parkinson’s Disease | Increased dopamine levels in brain was observed. | [42]      |
| 22    | Quetiapine fumarate    | Nano structured lipid carriers | Schizophrenia       | Achieved sustained release and Blood brain ratio showed 10 fold increase for NLCs administered through nasal route was observed. | [43]      |
| 23    | Quetiapine fumarate    | Nano liposomes      | Schizophrenia       | Maximum efficiency was observed and formulation shown better potential to deliver drugs to the brain. | [44]      |
| 24    | Risperidone            | Nano emulsion       | Depression          | Brain blood ratio of 0.617, 0.754 at 0.5h was increased. | [45]      |
| 25    | Risperidone            | Solid lipid Nanoparticles | Psychotic disorders | Better brain targeting delivery was observed. | [46]      |
| 26    | Resveratrol            | Nano emulsion       | Parkinson’s disease | Pharmacokinetic studies showed the higher concentration of drug in brain. | [47]      |
| 27    | Rosmarinic acid        | SLNs                | Huntington’s disease | The sustained release and better brain targetting delivery was observed. | [48]      |
| S. No | Drug name       | Drug delivery system     | Name of the disease           | Result                                                                 | Reference |
|-------|----------------|--------------------------|-------------------------------|------------------------------------------------------------------------|-----------|
| 28.   | Rivastigmine    | Nano structured lipid carriers | Alzheimer’s Disease           | Initial fast drug release followed by prolonged release over 48 h was estimated. | [49]      |
| 29.   | Saquinavir mesylate | Nano emulsion              | Neuro AlIDs                   | Nano emulsion with better brain targeting efficiency was observed.     | [50]      |
| 30.   | Safranal        | Nano emulsion             | Cerebral malaria              | The developed targeted formulation is safe and reached into brain.     | [51]      |
| 31.   | Thymoquinone    | Nanoparticles             | Alzheimer’s disease           | Reducing the systemic exposure and delivery of drug to the brain rapidly and more effectively was observed. | [52]      |
| 32.   | Teriflunomide   | Nanoparticles             | Multiple sclerosis            | Increased nasal residence time and formulation was safe for nasal administration. Brain/ plasma concentration ratio was increased to about 20 times was observed. | [53]      |
| 33.   | Valproic acid   | Nano particulate system   | Alzheimer’s disease           | Brain/ plasma concentration ratio was increased to about 20 times was observed. | [54]      |
| 34.   | Valproic acid   | Lipid nano carriers       | Bipolar disorders             | Better drug delivery into the brain was observed.                      | [55]      |
| 35.   | Zolmitriptan    | SLNs                      | Migraine                      | Formulation reached the brain with increased bioavailability and localized for 24h. | [56]      |

**Micro particulate drug delivery system**

| S. No | Drug name       | Drug delivery system     | Name of the disease           | Result                                                                 | Reference |
|-------|----------------|--------------------------|-------------------------------|------------------------------------------------------------------------|-----------|
| 36.   | Amisulpride     | Micro emulsion           | Schizophrenia                 | Nasal drug solution showed significantly high activity.               | [57]      |
| 37.   | Asenapine maleate | Micro emulsion            | Schizophrenia                 | Increased bioavailability and controlled targeting of drug to the brain was observed. | [58]      |
| 38.   | Clonazepam      | Micro emulsion           | Acute status epilepticus      | Rapid delivery of drug to the brain was observed.                     | [59]      |
| 39.   | Carbamazepine   | Micro emulsion           | Epilepsy                      | A Formulation free from nasal ciliotoxicity was developed and proved. | [60]      |
| 40.   | Diazepam        | Micro emulsion           | Status epilepticus            | Antiepileptic activity was improved.                                  | [61]      |
| 41.   | Nimodepine      | Micro emulsion           | Senil dementia                | Increased retention time of the formulation and enhanced brain delivery was observed. | [62]      |
| 42.   | Nimodepine      | Micelles                 | Global ischemia & epilepsy    | Improved brain bioavailability was observed.                          | [63]      |
| S. No | Drug name       | Drug delivery system | Name of the disease     | Result                                                                                                                                   | Reference |
|-------|-----------------|----------------------|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 43.   | Olanzapine      | Micro emulsion       | Schizophrenia           | Enhanced permeation of drug through nasal route was observed.                                                                           | [64]      |
| 44.   | Paliperidone    | Micro emulsion       | Schizophrenia           | Achieved desired therapeutic activity and delivered drug directly to the brain by nasal administration was observed.                       | [65]      |
| 45.   | Rizatriptan     | Microspheres         | Migraine                | Effective concentration of drug for brain targeting was observed.                                                                         | [66]      |
| 46.   | Tramadol HCL    | Microspheres         | CNS targeting           | Localization of drug in brain was observed.                                                                                            | [67]      |
| 47.   | Valproic acid   | Micro emulsion       | Epilepsy                | Better brain bioavailability was found.                                                                                            | [68]      |
| 48.   | Agomelatine     | Insitu gels          | Depression              | Enhanced nasal retention time and successful brain targeting by the intra nasal route was observed.                                       | [69]      |
| 49.   | Carbamazepine   | Nasal gel            | Epilepsy                | Fast and pronounced drug uptake in the brain was observed.                                                                               | [70]      |
| 50.   | Doxepine        | Biogels              | Mild & moderate depression | Effective drug delivery to brain by nasal route was observed.                                                                      | [71]      |
| 51.   | Geniposide      | Insitu nasal gel     | Alzheimer's disease     | More residence time and release of drug is controlled by gel was observed.                                                            | [72]      |
| 52.   | Methotrexate    | Nano gel             | Primary CNS targeting   | Increased methotrexate concentration in brain was observed.                                                                              | [73]      |
| 53.   | Naringenin      | Insitu gel           | Brain ischemia          | Enhanced brain bioavailability was observed.                                                                                            | [74]      |
| 54.   | Rasagiline mesylate | Nasal gel       | Parkinson's disease     | Four to six fold increased bioavailability of the drug was found .                                                                       | [75]      |
| 55.   | Sumatriptan succinate | Insitu gel         | Migraine & cluster headache | Enhanced nasal residence time and drug reached to the brain by nasal pathway.                                                           | [76]      |
| 56.   | Temozolamide    | Hydrogel formulation | Meta static melanoma & glioma | Increased residence time on nasal region was observed.                                                                                 | [77]      |
| 57.   | Tramadol HCL    | Insitu gels          | Depression              | Increased locomotor activity.                                                                                                            | [78]      |
| 58.   | Venalafaxine hydrochloride | Insitu gel        | Alzheimer's disease & depression | Estimated pharmacodynamics properties and proved more effective anti-depressant by nasal route.                                        | [79]      |
| 59.   | Vinopectin      | Insitu gel           | Dementia                | Enhanced bioavailability was observed.                                                                                            | [80]      |
| S. No | Drug name         | Drug delivery system | Name of the disease | Result                                                                                                                                        | Reference |
|-------|-------------------|----------------------|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 60.   | Carbamazepine     | Niosomes             | Epilepsy            | Improved invitro drug release was observed.                                                                                                | [81]      |
| 61.   | Donepezil         | Liposomes            | Alzheimer’s disease | The bioavailability of drug in brain was increased significantly.                                                                          | [82]      |
| 62.   | Dioleoylphosphatidyl choline | Cationic liposomes | Alzheimer’s disease | Improved therapeutic efficacy was observed.                                                                                               | [83]      |
| 63.   | Haloperidol       | Dendrimer            | Catalepsy           | Improved delivery of insoluble drugs to the brain was established.                                                                       | [84]      |
| 64.   | Resveratrol       | Transferosomes       | Alzheimer’s disease | Enhanced permeation through nasal mucosa was observed.                                                                                   | [85]      |
| 65.   | Zolmitriptan      | Niosomes & novasomes | Migraine            | Constituted advances in the management of migraine.                                                                                       | [86]      |

**Fig. 1. Different intra nasal Nano drug delivery systems**
brain and enhanced bioavailability by intra nasal route compared to intravenous and oral route of administration. Reports concluded that the dose required for nasal administration is less than the dose required for other route of administration. The present review highlighted the CNS disorders treated by intra nasal administration using various novel drug delivery systems which helps to have a pharmaceutical strategy for nasal administration to cross BBB.

4. CONCLUSION

Nasal drug delivery system is an alternative route of administration for the systemically acting drugs to improve patient acceptability and compliance compared to parenteral administration of drugs. Nasal drug absorption can be increased by using different approaches like increasing the nasal duration of drug, use of absorption enhancers and decreasing the mucociliary clearance. The nasal drug delivery system is beneficial in conditions like Parkinson’s disease, Alzheimer’s disease, (or) pain because it shows specific targeting of drugs to the brain. Nasal application of nanocarriers like solid lipid nanoparticles, liposomes and emulsion etc.to achieve efficient and safe approach for the treatment of CNS disorders. In near future, that more drugs will be introduced in the market in the form of nasal formulation with reduced doses and reduced cost of total treatment.

CONSENT

Not applicable.

ETHICAL APPROVAL

Not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Hutten KM, Rautio J. Prodrug an efficient way to reach delivery and targeting barriers. Current Topics in Medicinal Chemistry. 2011;11(18):2265-2287.

2. GoulatiS L, Shusta V. Protein engineering approaches for regulating blood brain barrier transcytosis. Current Opinion in Structural Biology. 2017;45:109-115.

3. Ayesha T, Ahmad S, Mehmood Y. Brain Targeting Drug delivery system. International Journal of Basic Medical Sciences and Pharmacy. 2015;5(1):32-40.

4. Ciriaci N, Catania VA, Rigalli JP. Modulation of expression and activity of ABC transporters by the phytoestrogen genistein, Impact on drug Disposition; current medicinal chemistry. 2016; 23(13):1370-1389.

5. Byeon HJ, Lee ES, Thao Q. Doxorubicin loaded nanoparticles consisted of cationic and mannose modified albumins for dual Targeting in brain tumours. Journal of Controlled Release. 2016; 225:301-313.

6. Stanley F. Parkinson’s disease Foundation coping with a diagnosis hyt://www.pdf.org/newly – diagnosed. 2017;1-68.

7. Keep RF, Spector R, Smith SR. A balanced view of choroid plexus structure and function: function on adult humans. Experimental Neurology. 2015; 267:78-86.

8. Joseph E , Narayan S; Adavnces in Brain targeting Drug delivery: Nanoparticulate systems ; Journal of pharmaceutical sciences ,2013; 3(1): 1-8.

9. Gabathuler R ; Approaches to transport therapeutic drugs across the blood brain barrier to treat brain diseases ; Neurobiology of diseases ,2010 ; 37(1) ; 48-57.

10. Lu CT, Wong HL, Zhao YZ. Current approaches to enhance CNS delivery of drug across the brain barriers; International Journal of Nanomedicine. 2014;9:2241-2257.

11. Bringas J, Cunningham J, Pivirott P. Bio distribution of adeno associated virus type -2 in non-human primates after convection enhanced delivery to brain; Molecular Therapy. 2008;16(7):1267-1275.

12. Brem H, Dimecot Li KW, Tyler BM. Local delivery of Mitoxantrone for the treatment of malignant brain tumours in rat. Journal of Neurosurg. 2002;97(50):1173-1178.

13. Gabathuler R. Approaches to transport therapeutic drugs across the blood brain barrier to treat brain diseases. Neurobiology of Diseases. 2010;37(1):48-57.

14. Dasagupta A, Liu M. Ultra sound mediated drug delivery to the brain: principles, progress and prospects. Drug Discovery Today Technologies. 2016;20:41-48.

15. Lu CT, Wong HL, Zhao YZ. Current approaches to enhance CNS delivery of drug across the brain barriers. International
16. Dissanayake S, Gamage S, Sarojini V. Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides. Journal of Controlled Release. 2011;250:62-76.

17. Brambilla L, Guidotti G, Ross D. Cell penetrating peptides: From basic research to clinics. Trends in Pharmacological Sciences. 2017;38(4):406-424.

18. Kumar TP, Raju PN, Sirisha B. Nasal drug delivery: A potential route for brain targeting. Pharma Innovations Journal. 2013;2(1):77-85.

19. Crowe TP, Greenlee HW, Kanthasamy AG, Walter HH. Mechanism of intra nasal drug delivery directly to the brain. Life Sciences. 2018;195:44-52.

20. Lu C-T, Wong HL, Zhao YZ; current approaches to enhance CNS delivery of drugs across the brain barriers; International journal of Nanomedicine ,2014; 9 ; 2241-2257.

21. Bergonzi MC, Guccione C, Pizzani V. Albumin nanoparticles for brain delivery: A comparison of chemical versus thermal methods & In vivo behaviour. Chem Med chem. 2016;11(16):1840-1849.

22. Jain K, Kuppusamy G, Sumeet S. Optimisation of artemether loaded nanostructured lipid carriers for intra nasal delivery using central composite design. Journal of Drug Delivery. 2014;22(7):940-954.

23. Prakash Chandra B, Pranay S, Preeti P, Washim K. Nose to brain delivery of Astaxanthin loaded solid lipid nanoparticles: fabrication, radio labelling, optimization & biological studies. Rsc Advances. 2016;6:10001-10010.

24. Elshafeey AH, Fatouh AM. International agomelatine solid lipid nanoparticles to enhance brain delivery: formulation, optimization and In vivo pharmacokinetics. Journal of Drug Design Development and Therapy. 2017;11:1815-1825.

25. Farid RM, Ismail F, Kaseem A, Youseef NAHA. A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel for brain targeting: preparation, characterization and in vivo evaluation. International Journal of Pharmaceutics. 2018;548(1):609-624.

26. Fazi M, Manish kumar, Shadab MD, Shadabiul H. Optimised nano formulation of bromocriptine for direct nose to brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra HPLC , mass spectrometry method. Journal of Drug Delivery. 2014;11(6):827-842.

27. Iłsan GA, Scioli S, Talevi A. Carbamazepine loaded solid lipid nanoparticles and nano structured lipid carriers: physico chemical characterization and In vitro, In vivo evaluation. Journal of Colloids, Surfaces and Biointerfaces. 2018;167:73-81.
36. Bikash M, Mishra S, Sinha SR. Galantamine loaded solid lipid nano particles for enhanced brain delivery: preparation, characterization, In vitro and In vivo evaluations. Journal of Drug Delivery. 2015;23(40):1434-1443.

37. Udairv S, Yaser S. Solid lipid nanoparticles for nose to brain delivery of haloperidol; in vitro drug release and pharmacokinetics evaluation. Acta Pharmaceutica Sinica B. 2014;4(6):454-463.

38. Nasar M. Development of an optimized hyaluronic acid based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery. Journal of Drug delivery. 2016;23(4):1444-1452.

39. Deepak S, Maheswari D, Manisha S, Philip G, Ravish R. Formulation and optimization of polymeric nanoparticles for intra nasal delivery of lorazepam using box–benken design; In vitro and In vivo evaluation. Biomed Research. 2014:1-15.

40. Giovanni R, Tersea M. Epilepsy disease and nose to brain delivery of polymeric nanoparticles: an overview. Journal of Pharmaceutics. 2019;118(11):1-21.

41. Kumar A, Seju U, Sawant KK. Development and evaluation of olanzapine loaded PLGA nanoparticles for nose to brain delivery; In vitro characterization and In vivo studies. Acta Biomaterilia. 2011; 7:4169-4176.

42. Guad R, Raj R, Sridhar V, Wairkar S. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery, development, characterization and in vivo anti –Parkinson activity . International Journal of Biological Macromolecules. 2018;109(1):27-35.

43. Bhavya M, Deva G, Nithin K, Praveen SD. Direct brain targeted nanostructured lipid carriers for sustained release of schizophrenic drug: Formulation, characterization & pharmacokinetic studies. Indian Journal of Pharmaceutical Education and Research. 2109;54(1):73-84.

44. Boche M, Varsha P. Quetiapine nanoemulsion for intra nasal drug delivery: evaluation of brain targeting efficiency. AAPS Pharma Sci Tech. 2017;18(3):686-696.

45. Babbar AK, Mukesh K, Mishra AK. Intra nasal nanolipid emulsion based brain targeting drug delivery system of risperidone. International Journal of Pharmaceutics. 2008;358:285-291.

46. Babbar AK, Chauha S, Patel S, Soni H. Brain targeting of risperidone loaded solid lipid nanoparticles by intra nasal route. Journal of drug targeting. 2011;19(6):468-474.

47. Ali J, Mustafa G, Pangeni R, Sharma S. Vitamin E loaded resveratrol nanolipid emulsion for brain targeting for the treatment of Parkinson’s disease by reducing oxidative stress. Journal of Nanotechnology. 2014;25(48):1-8.

48. Devendra D, Prakash A, Rahul B. Development, characterization and nasal delivery of Rosmarinic acid loaded solid lipid nanoparticles for the effective management of Huntington’s disease. Journal of Drug Delivery. 2014;22(7):931-939.

49. Alves J, Sara C, Silva AC. Double optimization of rivastigmine loaded nano structured lipid carriers for nose to brain delivery using the QbD approach; formulation variables & instrumental parameters. Journal of Pharmaceutics. 2020;12(7):599-610.

50. Agrawal A, Mahajan S, Pankaj P. Nano emulsion based intra nasal drug delivery system of saquinavir mesylate for brain targeting; Journal of Drug Delivery. 2013;21(2):148-154.

51. Ahmed N, Ahmad R, Ashafaq M. The effect of safranal loaded mucoadhesive nanoemulsion on oxidative stress markers in cerebral ischemia. An International Journal of Artificial Cells, Nanomedicine and Biotechnology. 2016;45(4):775-787.

52. Alam S, Islam F, Khan Z, Mustafa G, Manish kumar. Development and evaluation of thymoquinone encapsulated chitosan nanoparticles for nose to brain targeting: A pharmaco scintigraphic study. International Journal of Nano Medicine. 2012;7:5705-5718.

53. Dnyandev D, Kokare CR. Nano structured lipid carriers engineered for intra nasal delivery of trifluromide in multiple sclerosis, optimization and In vivo studies. Drug Development and Industrial Pharmacy. 2019;45(5):839-851.

54. Eskandari S, Majid T, Varshosaz J. Brain delivery of valproic acid via intra nasal administration of nanostructured lipid carriers, In vivo pharmacodynamics studies using rat electroshock model.
International Journal of Nano Medicine. 2011;6:363-371.

55. Eskandari S, Tabakhian M, Varshosaz J. Production and optimization of valproic acid nanostructured lipid carriers by taguchi design. Pharmaceutical Development and Technology. 2010;15(1):89-96.

56. Khalifa MK, Mostafa DAE. Zolmitriptan brain targeting via intra nasal route using solid lipid nanoparticle for migraine therapy: formulation, characterization, In vitro and In vivo assessment. International Journal of Applied Pharmaceutics. 2020;12(20):86-93.

57. Mrunali P, Patel RB, Suresh NH. Microemulsion for nasal delivery of asenapine maleate in treatment of schizophrenia: formulation considerations. Journal of Pharmaceutical Investigation. 2017;48(3):301-312.

58. Aibliash Teja G, Krishnaveni J, Ravikrishna V. Formulation & characterization of amisulpride microemulsion for brain targeting via intra nasal route pharmacodynamics evaluation in rat model . Journal of young pharmacists. 2020;12(23):25-31.

59. Babbar AK, Sharma RK, Tushar K. Intra nasal mucoadhesive micro emulsions of clonazepam: preliminary studies on brain targeting. Journal of Pharmaceutical Sciences. 2006;95(3):570-580.

60. Bharat G, Patel RB. Formulation consideration & characterization of micro emulsion drug delivery system for trans nasal administration of carbamazepine. Bulletin of Faculty of Pharmacy Cairo University. 2013;51(2):243-253.

61. Krishnaveni J, Rammeredy S. Brain targeting of chitosan based diazepam mucoadhesive micro emulsions via nasal route, formulation optimization, characterization, pharmacokinetic & pharmacodynamic evaluations. Journal of Drug Development & Industrial Pharmacy. 2018;45(1):1-33.

62. Dash RP, Misra M, Patak R. Role of mucoadhesive polymers in enhancing delivery of nimodipine microemulsion to brain via intra nasal route. Acta Pharmacetical Sinica B. 2014;4(2):151-160.

63. Hassan MR, Shamma R. Contribution of both olfactory and systemic pathways for brain targeting of nimodipine loaded lipo pluronic micelles: In vitro characterization & In vivo biodistribution study after intra nasal and intravenous delivery. Journal of Drug Delivery. 2017;24(1):181-187.

64. Mrunali P, Patel RB. Formulation & evaluation of micro emulsion based drug delivery system for intranasal administration of olanzapine. International Journal of Biomedical & Pharmaceutical Sciences. 2013;7(1):20-27.

65. Bharat GP, Mrunali R Patel, Patel RB. Paliperidone loaded mucoadhesive microemulsion in treatment of schizophrenia, formulation consideration. Journal of Pharmaceutical Innovation. 2013;8:195-204.

66. Kunal P, Shital B, Tora S. Development of rizatRIPTAN benzoate microsphere for nose to brain targeting; International Journal of Applied Pharmaceutics. 2016;8(4):69-74.

67. Avinash RT, Patel HS, Veena S. Design & development of nasal mucoadhesive microspheres containing tramadol HCL for CNS targeting; Drug Delivery. 2001;18(5):353-360.

68. Kawkikwar PS, Kulkarni NP, Yadav S. Formulation & evaluation of an anti-epileptic drug loaded micro emulsion for nose to brain delivery. Asian Journal of Pharmaceutics. 2009;1:1-10.

69. Elsheafeey AH, Fatouh AM; Agomelatine based insitu gels for brain targeting via the nasal route : statistical optimization ,In vitro & in vivo evaluation ; Journal of drug delivery ,2017 ; 24(1) ; 1077-1085 .

70. Fortuna A, Gilberto A, Serralheiro A. Intra nasal administration of carbamazepine to mice: A direct delivery pathway for brain targeting; European Journal of Pharmaceutical Sciences. 2014;60:32-39.

71. Anuja N, Hema N. Formulation & evaluation of thermo sensitive biogels for nose brain delivery of doxepine. Biomed Research International. 2014;1-10.

72. Jaing S, Wang Y, Wang H. Mucoadhesive, thermoreversible in situ nasal gel of geniposide for neuro degenerative diseases. Journal Pone. 2017;12(12):1-17.

73. Heidari R, Samani SM. In vitro & In vivo evaluation of methotrexate loaded hydrogel nanoparticles intended to treat primary CNS lymphoma via intra nasal administration. Journal of Pharmacy & Pharmaceutrical Sciences. 2018;21:305-515.

74. Ahmed N, Ahmed R, Ahmed FJ. Poloxamer–chitosan based naringenin
nano formulation used in brain targeting for the treatment of cerebral ischemia. Saudi Journal of Biological Sciences. 2020;27(1):500-517.

75. Aditya N, Patil S, Ravi PR. Nasal in situ gels for delivery of rasagiline mesylate: improvement in bioavailability & brain localization. Journal of Drug Delivery. 2015;22(7):903-910.

76. Pravin DC, Upendra G. Development of insitu gel for nasal delivery: design, optimization, In vitro & In vivo evaluation. Journal of Drug Delivery. 2013;21(1):62-73.

77. Imam S, Khan A, Sultan Y. Temozolomide loaded nano lipid based chitosan hydrogel for nose to brain delivery: characterization, nasal absorption, histopathology & cell line study. International Journal of Biological Macromolecules. 2018;116:1260-1267.

78. Atish Prakash, Kaur P, Tarun G, Vaidya B: Brain delivery of intra nasal in situ gel of nanoparticulated polymeric carriers, containing antidepressant drug, behavioural & biochemical assessment ; Journal of Drug Targeting. 2014;23(3):1-12.

79. Avachat A, Bhand walker M. Thermo reversible nasal insitu gel of venlafaxine HCL, formulation, characterization & pharmacodynamics evaluation. AAPS Pharm Sci Tech. 2013 ;14(1):101-102.

80. Aljaeid BM , Khalid M, Tarek AA. Superiority of TPGS- loaded micelles in the brain delivery of vinopincipal via administration of thermosensitive intra nasal gel. International Journal of Nanomedicine. 2019;14:5555-5567.

81. Ahmed MF, Ghada E, Rehami A. Carbamazepine loaded vesicular structures for enhanced brain targeting via intra nasal route ,optimization, In vitro evaluation & In vivo study. International Journal of Applied Pharmaceutics. 2019;11(4):264-274.

82. Asmari AK, Fatani A, Tariq M, Ullah Z. Preparation, characterization & In vivo evaluation of intra nasally administered liposomal formulation of donepezil. Journal of Drug Design, Development and Therapy. 2016;12(10):205-215.

83. Bowey K, Tabrizian M. 2-Dioleoyl 5n glycerol-3-phosphocholine based nano liposomes as an effective delivery for 17 β estradiol. Journal of Drug Design, Development & Therapy. 2014; 86(3):369-375.

84. Jayant B, Katere YK, Mishra RK, Ritesh P. Daya. Brain targeting of a water insoluble Antipsychotic drug Haloperidol via the intra nasal route using PAMAM dendrimer. Molecular Pharmaceutics. 2015;12(9): 3380-3388.

85. Heba F. Salem, Kharshoum RM, Naguib DM. Brain targeting of resveratrol through intranasal lipid vesicles labelled with gold nanoparticles: In vivo evaluation and bioaccumulation investigation using computed tomography and histopathological examination. Journal of Drug Targeting. 2019;27(10):1127-1134.

86. KandilSM, Mohamed M, Mahmoud TM. Preparation & evaluation of optimized zolmitriptan niosomal emulgel. Journal of Drug Development & Industrial Pharmacy. 2019;45(7):1157-1167.